Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
2
Neutral
7
Bullish
5
Bearish
6
Neutral
7
Bullish
33
Bearish
4
Neutral
0
Bullish
28
Discovery themes featuring this stock
Aster DM Healthcare is a prominent healthcare provider across the GCC and India, offering a complete circle of care through hospitals, clinics, labs, and pharmacies.
Aster is experiencing strong sequential revenue growth with a 15% increase YoY in Q3FY26, driven by expanding patient volumes and effective cost management, evidenced by a 22% rise in operating EBITDA.
The company is executing an ambitious expansion strategy, planning to add over 4,000 beds, aimed at scaling its hospitals' capacity for future demands, securing its position as one of India’s leading healthcare networks.
Aster’s strategic merger with QCIL is positioned to enhance its service capabilities and expand its footprint in newer markets, while identifying operational synergies worth between 10-15% of pro-forma EBITDA.
Innovation in medical technology and patient care models, such as strategic focus on high-value specialties like oncology, supports ongoing growth, aiming to elevate clinical offerings and improve profit margins.
Healthcare Services
Hospital
35,662 Cr
Low Risk
103.9
55.9
1.8
8.5
732.00
449.55
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1765.00 | 37,307 Cr | 46.02 | 9.19 | 0.25 | 20.82 | 17.75 | 10.07 | ||
658.90 | 35,662 Cr | 103.87 | 8.52 | 0.70 | 8.18 | 10.11 | 4.60 | ||
1001.30 | 29,286 Cr | 52.41 | 7.90 | 0.00 | 15.15 | 16.83 | 9.50 | ||
680.00 | 27,283 Cr | 90.67 | 12.02 | 0.00 | 14.80 | 10.88 | 4.75 | ||
421.95 | 14,087 Cr | 106.50 | 7.30 | 0.00 | 5.94 | 9.26 | 4.25 | ||
1254.90 | 12,664 Cr | 49.47 | 8.34 | 0.24 | 16.72 | 17.60 | 10.05 | ||
195.70 | 9,338 Cr | 35.26 | 4.77 | 0.00 | 20.61 | 19.00 | 0.00 | ||
| Median: 7 Co. | — | 680.00 | 27,283 Cr | 52.41 | 8.34 | 0.00 | 15.15 | 16.83 | 4.75 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Aster DM Healthcare Ltd (ASTERDM) is currently trading at 678.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Aster DM Healthcare is a prominent healthcare provider across the GCC and India, offering a complete circle of care through hospitals, clinics, labs, and pharmacies. Aster is experiencing strong sequential revenue growth with a 15% increase YoY in Q3FY26, driven by expanding patient volumes and effective cost management, evidenced by a 22% rise in operating EBITDA. The company is executing an ambitious expansion strategy, planning to add over 4,000 beds, aimed at scaling its hospitals' capacity for future demands, securing its position as one of India’s leading healthcare networks. Aster’s strategic merger with QCIL is positioned to enhance its service capabilities and expand its footprint in newer markets, while identifying operational synergies worth between 10-15% of pro-forma EBITDA. Innovation in medical technology and patient care models, such as strategic focus on high-value specialties like oncology, supports ongoing growth, aiming to elevate clinical offerings and improve profit margins.
Over the past 52 weeks, Aster DM Healthcare Ltd has traded between a low of ₹449.55 and a high of ₹732.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Aster DM Healthcare Ltd has a market capitalization of approximately 35,662.27. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Aster DM Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 103.87 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 35,662.27 Cr, Aster DM Healthcare Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Aster DM Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Aster DM Healthcare Ltd is 103.87. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Hong Kong-based private equity firm Olympus Capital Asia, through its arm Olympus Capital Asia Investments, sold the stake.
To seek shareholder approval for two key resolutions: appointing founder Dr. Azad Moopen as Executive Director with a remuneration of up to ₹10 crore, and authorizing financial assistance of up to ₹1,500 crore to group companies.
The shareholders of Aster DM Healthcare approved the merger with Quality Care India Limited with an overwhelming 96.68% of votes in favor of the amalgamation scheme.
Aster DM Healthcare has earmarked a capital outlay of approximately ₹4,000 crore to add about 4,080 beds across its network in India over the next few years.
Postal Ballot Results
Scrutinizer reports postal ballot (e‑voting Mar 14–Apr 12, 2026): all resolutions passed; appointment of Dr. M.A. Moopen approved (promoter votes 100%, overall 99.84% in favour) and loans/guarantees under Sec.185 approved overall (75.57% in favour).
Postal ballot results
Aster DM Healthcare submitted the Scrutinizer's Report (dated Apr 15, 2026) confirming all resolutions in the Mar 10, 2026 postal ballot were passed by requisite majority; notable items: appointment of Dr. M.A. Moopen and approval under Section 185 (voting details enclosed).
Postal Ballot Outcome
Aster DM Healthcare reports postal ballot results (Scrutinizer report dated Apr 15, 2026): all resolutions passed, including appointment of Dr. Mandayapurath Azad Moopen as Executive Director (99.84% in favour) and approval under Section 185 (75.57% in favour).
Postal Ballot Results
Aster DM Healthcare’s scrutinizer report (15 Apr 2026) confirms shareholders approved two special resolutions — appointment of Dr. M.A. Moopen as Executive Director and authorization for loans/guarantees under Section 185 — passed with ~99.84% and ~75.57% votes in favour respectively.
